after infliximab treatment; 2) the short-term outcome of a new series of severe UC patients treated with a three-infusion regimen of infliximab.
OC3.11.6 THIOPURINE-METHYL-TRANSFERASE (TPMT) ACTIVITY IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS IS NOT AFFECTED BY CO-ADMINISTRATION OF SALYCILATES
Background and aim: Thiopurines are widely used in inflammatory bowel disease (IBD). It has been reported that co-administration of aminosalicylates (mesalamine -5ASA-or sulphasalazine -SASP-) significantly inhibits TPMT activity, and may result in higher rates of thiopurine toxicity. Aim of this study was to analyse the effect of 5ASA or of oral steroids on TPMT activity.
Material and methods:
Within a study protocol approved by local Ethical Committee, all consecutive patients (n=169) attending IBD outpatients were recruited. A blood sample was drawn, and intra-erythrocyte TMPT activity was analysed by means of a standardised high pressure liquid chromatography (HPLC) assays. In patients undergoing thiopurine treatment, we also evaluated the levels of 6-thioguanosinenucleotides (6TGN) and 6-methyl-mercaptopurine (6MMP). Results: Up to now 169 IBD patients were enrolled (79 Crohn's disease, 86 ulcerative colitis, 4 indeterminate colitis). Concomitant medications were: 5ASA in 118 (70%), systemic steroids (GCS) in 16 (10%), azathioprine (AZA) in 64 (38%) cases, respectively. No difference in TPMT activity was observed according to gender, age, diagnosis, use of thiopurines or other clinical variables was noted. Median TPMT activity was 26.84 (95%CI 24.40-28.63) and 30.32 (825.13-39.8) nmol/h/g Hgb in patients on 5ASA (5ASA+, n=118) and not on 5ASA (5ASA-, n=51), respectively (p=0.124). Data regarding median TPMT activity, and metabolites levels according to AZA status are reported in Table 1 ; p values are non-significant for all comparisons. 
Conclusions:
Aminosalicylates were prescribed in a large proportion of IBD patients considered in the study. No significant effects of 5ASA on TPMT activity were noted, although a non-significant trend towards a lower TPMT was observed. However this mild effect does not interfere with metabolites levels. Observation on a larger group of patients in ongoing in order to confirm these observations. If these data will be confirmed co-administration of aminosalicylates and thiopurines may be considered safe. # L. Inflammatory bowel diseases 3. Ulcerative colitis
